This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Genentech’s ocular implant drugdeliverysystem for treatment of macular degeneration has received approval from the US Food and Drug Administration (FDA). Susvimo delivers ranibizumab via a port deliverysystem into a surgically placed implant in the eye, allowing for continuous delivery of the drug.
Interestingly, over the past few years, drug developers focused on non-respiratory diseases have also shifted their attention towards intranasal drug formulations. This can be attributed to ease of delivery, increased bioavailability and by-pass of first-pass metabolism offered by this type of route of administration.
$158 Billion DrugDeliverySystems (DDS) Markets – Global Forecast to 2027 – Necessity of DrugDeliverySystems for Enhancing Therapeutic Efficiency and Safety Profile of Drugs – ResearchAndMarkets.com $158 Billion DrugDeliverySystems (DDS) Markets – Global Forecast to … Continue reading →
Global Biotechnology, Drug Development and DrugDeliverySystems Nanoparticles Markets, 2019-2020 & 2025 – ResearchAndMarkets.com Global Biotechnology, Drug Development and DrugDeliverySystems Nanoparticles Markets, 2019-2020 & 2025 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Nanoparticles in Biotechnology, (..)
2020 Insights on the Global Markets and Technologies for Advanced DrugDeliverySystems – ResearchAndMarkets.com 2020 Insights on the Global Markets and Technologies for Advanced DrugDeliverySystems – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Global Markets and Technologies for Advanced DrugDelivery … (..)
Global Inhaled and Intranasal Products 2020-2030: Contract Service Providers Market – Focus on Drugs and DrugDeliverySystems – ResearchAndMarkets.com Global Inhaled and Intranasal Products 2020-2030: Contract Service Providers Market – Focus on Drugs and DrugDeliverySystems – ResearchAndMarkets.com … Continue reading (..)
Global Microneedle DrugDeliverySystemsMarket (2021 to 2027) – Featuring Zosano Pharma, Raphas and Endoderma Among Others – ResearchAndMarkets.com Global Microneedle DrugDeliverySystemsMarket (2021 to 2027) – Featuring Zosano Pharma, Raphas and Endoderma Among Others – ResearchAndMarkets.com … Continue reading → (..)
Global Microneedle DrugDeliverySystemsMarket Report 2021: COVID-19 Impact Analysis, Growth and Changes to 2030 – ResearchAndMarkets.com Global Microneedle DrugDeliverySystemsMarket Report 2021: COVID-19 Impact Analysis, Growth and Changes to 2030 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Microneedle Drug (..)
Contract marketing companies support pharmaceutical companies in creating, improving, and maintaining their brand, as well as reducing risk, and ensuring better product placement in the market. Identifying the top commercial dose (non-sterile) companies in contract marketing.
Global Transdermal DrugDeliverySystemsMarket Research Report 2021: Industry Trends, Share, Size, Growth, Opportunity and Forecasts, 2015-2020 & 2021-2026 – ResearchAndMarkets.com Global Transdermal DrugDeliverySystemsMarket Research Report 2021: Industry Trends, Share, Size, Growth, Opportunity and Forecasts, 2015-2020 … Continue (..)
In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Key innovation: Leading companies in nanoparticles for drugdelivery. Bristol-Myers Squibb is the leading patent filer in nanoparticles for drugdelivery.
Hence, a precision therapy or we can say a target therapy (involving intracellular drugdelivery) is much needed to all the patients suffering from cancer. Here is how the intracellular drugdelivery comes into action for majority of the fatal diseases that requires target therapy. The answer is yes. The answer is yes.
In order to promote the use of exosomes in various therapeutic applications including targeted drugdelivery vehicles, engineered exosomes and many more, there are a number of companies that offer services related to the isolation, purification, characterization or quantification of exosomes. Want additional details on the pipeline?
Over the last two decades, the pharmaceutical industry has observed a paradigm shift from conventional drugdelivery strategies to the long-acting drugdelivery (LADD) of products to treat several disease indications, such as ophthalmic disorders, oncological disorders, neurological disorders and infectious diseases.
However, several drugdelivery devices that enable patients to self-administer their respective medications are now available. Subcutaneous biologics – current market landscape. Subcutaneous drugdeliverysystems – the helping hand for patients. Of these, 50 players have approved subcutaneous biologics.
However, it is important to highlight that there are still several challenges which need to be addressed in order to develop biologic drugs capable of effectively being administered via the oral route without undergoing significant losses in specificity and / or bioavailability. Oral Protein / Peptide-based Drugs.
Outsourcing offers several benefits to the developers including cost saving opportunities, increased operational efficiencies, expedited time-to-market, access to advanced capabilities and technologies, validated quality control setup, flexibility, risk sharing and, in several cases, regulatory support. Our Social Media Platform. Web: [link].
Recent years started witnessing the emergence of novel treatment approaches that have been keeping the Retinal vein occlusion market in a hyped-up state. Looking at the potential of the pipeline therapies they hold once approved, pharmaceutical companies are charting out a seemingly exciting course in the market.
Nano-based deliverysystems are on the rise, as they enable manufacturers to deliver therapeutic agents to specific targeted tissue in a more controlled manner. Data indicates that the global nanopharmaceutical drugsmarket size reached USD 53.85 Billion in 2021 and is expected to reach USD 102.4 Billion in 2030.
The six-page statement explains that “Brand drug manufacturers may be harming generic competition through the improper listing of patents in the. Of course, the statute says that only drug formulation, composition, or method of use patents are listable, but FDA has not defined the scope of the “drug” that must be covered by the patent.
However, certain biological targets have long eluded drug development efforts. Likewise, there are several other targets that have not yet been successfully drugged and researchers are making significant efforts to identify novel approaches to target them. To learn more, please click New Frontiers Cancer Therapy market report.
However, for such a burdensome and highly prevalent sight-threatening eye disorder, the Retinal vein occlusion treatment market has no curative option to offer. Retinal vein occlusion drugmarket. Intraocular injections of steroids are another potential treatment for eyes that don’t respond to anti-VEGF drugs.
The US Food and Drug Administration (FDA) also has concerns about the toxic effects of EtO and thus is continuing to encourage new ways to sterilize medical devices and strategies to mitigate the emission levels of EtO while achieving adequate sterilization. Live and On-Demand: Tuesday, September 20, 2022, at 11am EDT (4pm BST/UK).
Over the last decade, one of the major challenges faced by pharmaceutical companies across the globe is low drug solubility. In fact, it has been observed that around 40% of the pharmaceutical drugs approved by regulatory organizations exhibit poor bioavailability / solubility.
Since the approval of Soliris® in 2007, an anti-C5 antibody, the field of complement drug discovery has gained significant attention. Next Generation Complement Therapeutics – Current Market Landscape. The market is characterized by a mix of well-established and small firms. Next Generation Complement Therapeutics Market.
Over the last decade, one of the major challenges faced by pharmaceutical players across the globe is low drug solubility. As a matter of fact, recently many drug developers have initiated formulating novel therapeutic interventions that utilize nanoparticles as a major component ( nanomedicines ). Nanoparticles Contract Manufacturing.
The company developing drug product through such an intense process, use to consider container closure system only for packaging of the product. [1] Container Closure Integrity Testing Services Market. In earlier times, container closure integrity testing was not regarded as an essential step in the process of manufacturing.
By charting new waters and creating uncontested market spaces, companies can differentiate themselves and unlock unprecedented growth opportunities. In this blog post, I’ll explore how pharma / biotech companies can leverage the blue ocean and red ocean strategy to make waves in the market.
In the past decade, more than 1,500 clinical trials have been registered for evaluating drug therapies targeting myeloid cells. Driven by lucrative investments, extensive R&D efforts and contributions from various big pharma players, the myeloid cell targeting therapeutics market is expected to grow at a steady pace. Web: [link].
The production of such drug products requires skilled labor, stringent manufacturing protocols and specialized expertise. Additionally, they also require appropriate drugdeliverysystems to efficiently administer the intervention (in a manner that they can avoid degradation by cellular endonucleases).
Certain areas where this technology is working hand-in-hand with healthcare are: Unsustainable healthcare systems into sustainable ones Equalizing the relationship between medical professionals and patient Provide cheaper, faster and more effective solutions for diseases. Drug Development. Management & Administration.
Given the evident benefits of biologics over small molecule drugs (including high efficacy, target specificity and favorable safety profiles), the biopharmaceutical market is poised to witness continued and consistent growth over the next several years. Future Evolution of Biopharmaceutical Excipient Manufacturing Market.
In recent years, liposomes have garnered significant interest of researchers, as well as industry players, owing to their potential in diagnosis and treatment of various diseases, with a focus on delivering drugs and genetic material.
Oligonucleotide Synthesis, Modification and Purification Services Market. You may also be interested in the following titles: Live Biotherapeutic Products and Microbiome Manufacturing Marke t Next Generation Complement Therapeutics Market Intranasal Therapeutics and DrugDeliverySystemsMarket. Web: [link].
However, research related to metabolites is essential to increase the understanding of molecular level interactions, functions, modifications and regulations in cells, therefore, the field of metabolomics plays a vital role in biomarker discovery for early disease diagnosis and prognosis as well as for drug discovery and development processes.
Driven by the increasing need for safe and efficient medical devices and drugdeliverysystems, the pharmaceutical polymers / medical grade polymers domain is advancing significantly. The pharmaceutical polymers market is highly fragmented, featuring the presence of established companies, as well as emerging start-ups.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content